Samantha Budd-Haeberlein, Ph.D.

Chief Medical Officer, Meilleur Technologies and Enigma Biomedical Group, overseeing the development of therapeutic solutions to combat neurodegenerative diseases. Over the past 23 years, Samantha has recently held the position of Senior Vice President and Head of Neurodegeneration at Biogen, leading approvals of the first new therapeutics in Alzheimer’s disease.